Lingfeng Yang

发表

Prevalence of Established Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in the UK

Tongtong Wang, S. Rajpathak, D. Lautsch, 2019, Diabetes Therapy.

Factors associated with switching from sulphonylureas to dipeptidyl peptidase 4 inhibitors among patients with type 2 diabetes in the United States

K. Khunti, S. Rajpathak, Lingfeng Yang, 2021, Diabetes, obesity & metabolism.

Representativeness of the VICTORIA Trial Population in Clinical Practice: Analysis of the PINNACLE Registry.

Mahesh J. Patel, J. Butler, R. Mentz, 2021, Journal of cardiac failure.

Systemic therapy, survival and end-of-life costs for metastatic triple-negative breast cancer: retrospective SEER-Medicare study of women age ≥65 years.

K. Hirshfield, A. Haiderali, Lingfeng Yang, 2021, Future oncology.

Real-World Treatment Patterns in Metastatic Castration-Resistant Prostate Cancer Across Europe (France, Germany, Italy, Spain, and the United Kingdom) and Japan

Jeri Kim, A. Leith, S. Ghate, 2022, Advances in Therapy.

Impact of next-generation hormonal agents on treatment patterns among patients with metastatic hormone-sensitive prostate cancer: a real-world study from the United States, five European countries and Japan

Jeri Kim, A. Leith, S. Ghate, 2022, BMC Urology.

Factors associated with the discontinuation of dipeptidyl peptidase-4 inhibitors (DPP-4is) after initiation of insulin

J. E. Matos, K. Iglay, S. Rajpathak, 2019, Current medical research and opinion.

Secondary metformin monotherapy failure in individuals with type 2 diabetes mellitus

L. Blonde, K. Iglay, S. Rajpathak, 2021, BMJ Open Diabetes Research & Care.

Prognostic Interplay Between COVID-19 and Heart Failure With Reduced Ejection Fraction

D. Lautsch, S. Greene, Lingfeng Yang, 2022, Journal of Cardiac Failure.

N‐terminal pro‐B‐type natriuretic peptide testing patterns in patients with heart failure with reduced ejection fraction

J. Januzzi, D. Lautsch, Lingfeng Yang, 2021, ESC heart failure.

Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States

K. Iglay, R. Carr, S. Rajpathak, 2020, Patient preference and adherence.

Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK

K. Iglay, R. Carr, S. Rajpathak, 2022, BMJ Open Diabetes Research & Care.

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study

E. Plimack, M. Voss, B. Rini, 2018, Journal of Immunotherapy for Cancer.

Single Dose of SHR-1222, a Sclerostin Monoclonal Antibody, in Healthy Men and Postmenopausal Women With Low Bone Mass: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Phase I Study

X. Yan, X. Fan, Zhiguang Zhou, 2021, Frontiers in Pharmacology.

Medication use by US patients with pulmonary hypertension associated with chronic obstructive pulmonary disease: a retrospective study of administrative data

E. Bajwa, S. Rajpathak, D. Lautsch, 2022, BMC Pulmonary Medicine.

Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors

R. Ionescu-Ittu, N. Shore, M. Duh, 2021, Advances in Therapy.

Real-world homologous recombination repair mutation testing in metastatic castration-resistant prostate cancer in the USA, Europe and Japan.

Jeri Kim, A. Leith, S. Ghate, 2022, Future oncology.

Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials

D. Hill, P. Scheltens, A. Gass, 2016, Alzheimer's Research & Therapy.

Long-Term Real-World Outcomes of First-Line Pembrolizumab Monotherapy for Metastatic Non-Small Cell Lung Cancer With ≥50% Expression of Programmed Cell Death-Ligand 1

V. Velcheti, M. Pietanza, Xiaohan Hu, 2022, Frontiers in Oncology.

Long-term safety and tolerability of bapineuzumab in patients with Alzheimer’s disease in two phase 3 extension studies

J. Pariente, R. Black, A. Ivanoiu, 2016, Alzheimer's Research & Therapy.

Outcomes at 7 years post‐transplant in black vs nonblack kidney transplant recipients administered belatacept or cyclosporine in BENEFIT and BENEFIT‐EXT

L. Rostaing, M. Abouljoud, F. Vincenti, 2018, Clinical transplantation.

Impact of diabetes and previous myocardial infarction on long-term survival: 25-year mortality follow-up of primary screenees of the Multiple Risk Factor Intervention Trial.

Lynn E Eberly, Gabriele Riccardi, Jeremiah Stamler, 2004, Archives of internal medicine.

Safety and tolerability of desvenlafaxine in children and adolescents with major depressive disorder.

R. Findling, J. Groark, Sara Ramaker, 2014, Journal of child and adolescent psychopharmacology.

Impact of incident diabetes and incident nonfatal cardiovascular disease on 18-year mortality: the multiple risk factor intervention trial experience.

L. Eberly, R. Prineas, Jerome D. Cohen, 2003, Diabetes care.

Clinical and Economic Burden of Chronic Heart Failure and Reduced Ejection Fraction Following a Worsening Heart Failure Event

J. Butler, Lingfeng Yang, Joanne E. Brady, 2020, Advances in Therapy.

Pulmonary function as a predictor of lung cancer mortality in continuing cigarette smokers and in quitters.

L. Kuller, L. Eberly, J. Ockene, 2003, International journal of epidemiology.

PPA_A_277676 2337..2345

K. Iglay, R. Carr, S. Rajpathak, 2020 .

Level of glycemic control among US type 2 diabetes mellitus patients on dual therapy of metformin and sodium–glucose cotransporter 2 inhibitor: a retrospective database study

K. Iglay, S. Rajpathak, D. Lautsch, 2020, Current medical research and opinion.

Beyond Frontline Therapy with Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: A Real-World US Study.

R. Ionescu-Ittu, Jeri Kim, N. Shore, 2021, Clinical genitourinary cancer.

Pharmacokinetics and Tolerability of Single-Ascending Doses of Desvenlafaxine Administered to Children and Adolescents with Major Depressive Disorder.

R. Findling, J. Groark, Sara Ramaker, 2016, Journal of child and adolescent psychopharmacology.

Treatment patterns and clinical outcomes among patients <65 years with a worsening heart failure event

J. Butler, Lingfeng Yang, L. Djatche, 2021, European journal of heart failure.

Nivolumab monotherapy in metastatic urothelial carcinoma: Longer-term efficacy and safety results from the CheckMate 032 study.

D. Jäger, P. Sharma, P. Ott, 2018 .

Symptomatic and Functional Improvement in Employed Depressed Patients: A Double-Blind Clinical Trial of Desvenlafaxine Versus Placebo

B. Dunlop, S. Lubaczewski, C. Guico-Pabia, 2011, Journal of clinical psychopharmacology.

Using Deep Learning to Identify High-Risk Patients with Heart Failure with Reduced Ejection Fraction

Justin L. Vincent, B. Ru, Lingfeng Yang, 2021, Journal of health economics and outcomes research.

Early triple-negative breast cancer in women aged ≥65: retrospective study of outcomes, resource use and costs, 2010-2016.

K. Hirshfield, A. Haiderali, Lingfeng Yang, 2020, Future oncology.

Atazanavir Plus Cobicistat: Week 48 and Week 144 Subgroup Analyses of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial§

J. Gallant, G. Moyle, H. Cao, 2017, Current HIV research.

Multiple doses of SHR-1222, a sclerostin monoclonal antibody, in postmenopausal women with osteoporosis: A randomized, double-blind, placebo-controlled, dose-escalation phase 1 trial

X. Yan, Bo Wu, J. Shentu, 2023, Frontiers in Endocrinology.

Symptomatic and Functional Improvement in Employed Depressed Patients: A Double-Blind Clinical Trial of Desvenlafaxine Versus Placebo

B. Dunlop, S. Lubaczewski, C. Guico-Pabia, 2011, Journal of clinical psychopharmacology.